BaseSpace
Correlation
Engine-Public
Sign In
Register
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs7903146
,
NEUROG3
,
Angiogenesis
,
Allergy to pollen
,
Hypothalamus
,
Hematopoietic cell
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
cep- 1347
Summary
General Info
Curated Studies
Most Correlated Studies
There were no matches for cep- 1347
Explore Curated Studies Results
Literature
Most Relevant Literature
CEP-1347 Boosts Chk2-Mediated p53 Activation by Ionizing Radiation to Inhibit the Growth of Malignan…
The Novel MDM4 Inhibitor CEP-1347 Activates the p53 Pathway and Blocks Malignant Meningioma Growth I…
CEP-1347 Dually Targets MDM4 and PKC to Activate p53 and Inhibit the Growth of Uveal Melanoma Cells.
Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Typ…
Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease
A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Particip…
A Study to Evaluate the Efficacy and Safety of CEP-33457 in Participants With Systemic Lupus Erythem…
A Longitudinal Observational Follow-up of the PRECEPT Study Cohort
Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ